DUBLIN, Ireland--(BUSINESS WIRE)--Nov. 17, 2005--Gilead Sciences, Inc. (Nasdaq:GILD) today announced the presentation of preliminary 24-week data from the COMET (Combination of Efavirenz and Truvada) study at the 10th European AIDS Conference (EACS), November 17-20, 2005 in Dublin, Ireland. Data suggest that in HIV-infected treatment-experienced patients who switched from twice-daily Combivir(R) (lamivudine 150 mg/zidovudine 300 mg) to once-daily Truvada(R) (emtricitabine and tenofovir disoproxil fumarate), both in combination with efavirenz, the percentage of patients that achieved virologic suppression below 50 copies/mL was significantly higher at week 24 compared to baseline. Hemoglobin levels also increased significantly from baseline. Data will be presented (Poster #PE7.3/5) by study investigator Peter Ruane, MD of Lifesource Medical Inc. in Los Angeles, California.
